<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2912211522
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MONTEK 5 mg 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MONTELUKAST SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Chewable tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        64.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AJA PHARMACEUTICAL INDUSTRIES" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1916]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>MONTEK</strong> is a leukotriene receptor antagonist that blocks substances called leukotrienes. Leukotrienes cause narrowing and swelling of airways in your lungs.</p><p>By blocking leukotrienes, <strong>MONTEK</strong> improves asthma symptoms and helps control asthma.</p><p>Your doctor has prescribed <strong>MONTEK</strong> to treat your child&rsquo;s asthma, preventing asthma symptoms during the day and night.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>MONTEK</strong> is used for the treatment patients who are not adequately controlled on their medication and <strong>need additional therapy.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>MONTEK</strong> may also be used as <strong>an alternative treatment to be inhaled corticosteroids</strong> for patients who have not recently taken oral corticosteroids for their asthma and have shown that they are unable to use inhaled corticosteroids.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>MONTEK</strong> also helps <strong>prevent the narrowing of airways</strong> triggered by exercise for patients 2 years of age and older.</p><p>Your doctor will determine how MONTEK should be used depending on the symptoms and severity of your child&#39;s asthma.</p><p><strong>What is asthma?</strong></p><p>Asthma is a long-term disease.</p><p>Asthma includes:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty breathing because of narrowed airways. This narrowing of airways worsens and improves in response to various conditions.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sensitive airways that react to many things, such as cigarette smoke, pollen, cold air, or exercise.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling (inflammation) in the lining of the airways.</p><p>Symptoms of asthma include coughing, wheezing, and chest tightness.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tell your doctor about any medical problems or allergies your child has now or has had.</p><p><strong>Do not give MONTEK to your child if he/she</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Is allergic (hypersensitive) to montelukast or any of the other ingredients of MONTEK (see 6. Further information).</p><p><strong>Warning and precautions</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your child&rsquo;s asthma or breathing gets worse, tell your doctor immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>MONTEK is not meant to treat acute asthma attacks.</strong> If an attack occurs, follow the instructions your doctor has given you for your child. Always have your child&rsquo;s inhaled rescue medicine for asthma attacks with you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is important that your child take all asthma medications prescribed by your doctor. <strong>MONTEK should not be used instead of other asthma medications your doctor has prescribed for your child.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any patient on anti-asthma medicines, be aware that if he/she develops a combination of symptoms such as flu-like illness, pins and needles or numbness of arms or legs, worsening of pulmonary symptoms, and/or rash, you should consult your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You or your child should not take acetyl-salicylic acid (aspirin) or <strong>other anti-inflammatory medicines</strong> (also known as non-steroidal anti-inflammatory drugs or NSAIDs) if they make his/her asthma worse.</p><p><strong>Children and adolescents</strong></p><p>Do not give this medicine to children less than 2 years of age.</p><p><strong>Taking other medicines</strong></p><p>Please tell your doctor or pharmacist if your child is taking or has recently taken other medicines, including those obtained without a prescription.</p><p>Some medicines may affect how these tablets works, or these tablets may affect how your child&rsquo;s other medicines work.</p><p>Tell your doctor if your child is taking the following medicines before starting this medicine:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenobarbital (used for treatment of epilepsy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenytoin (used for treatment of epilepsy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rifampicin (used to treat tuberculosis and some other infections)</p><p><strong>Taking MONTEK with food and drink</strong></p><p>These tablets should not be taken immediately with food; they should be taken at least 1 hour before or two hours after food.</p><p><strong>Pregnancy and breast-feeding</strong></p><p><em>Use in pregnancy</em></p><p>Women who are pregnant or intend to become pregnant should consult their doctor before taking this medicine. Your doctor will assess whether you can take this medicine during this time.</p><p><em>Use in breast-feeding</em></p><p>It is not known if montelukast appears in breast milk. You should consult your doctor before taking this medicine if you are breast-feeding or intend to breast-feed.</p><p><strong>Driving and using machines</strong></p><p>This subsection is not applicable for the MONTEK 4mg chewable tablets since they are intended for use in children 2 to 5 years of age, however the following information is relevant to the active ingredient, montelukast.</p><p>This medicine is not expected to affect your ability to drive a car or operate machinery. However, individual responses to medication may vary. Certain side effects (such as dizziness and drowsiness) that have been reported very rarely with these tablets may affect some patients&rsquo; ability to drive or operate machinery.</p><p><strong>Important information about some of the ingredients of MONTEK</strong></p><p>MONTEK 5 mg chewable tablets contain aspartame, a source of phenylalanine. If your child has phenylketonuria (a rare, hereditary disorder of the metabolism) you should take this into account that each 5 mg chewable tablet contains phenylalanine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always have your child take this medicine as your doctor has told you. You should check with your child&rsquo;s doctor or pharmacist if you are not sure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your child should take only one tablet of this tablets once a day as prescribed by your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It should be taken even when your child has no symptoms or if he/she has an acute asthma attack.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicine is for oral use.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The tablets are to be chewed before swallowing.</p><p><strong>For children 2 to 5 years of age:</strong></p><p>One MONTEK 4 mg chewable tablet daily to be taken in the evening. The tablet should not be taken immediately with food; it should be taken at least 1 hour before or 2 hours after food.</p><p><strong>For children 6 to 14 years old</strong></p><p>MONTEK 5 mg chewable tablets are available. The tablet should not be taken immediately with food; it should be taken at least 1 hour before or 2 hours after food. If your child is taking this medicine, be sure that he/she does not take any other medicines that contain the same active ingredient, montelukast.</p><p><strong>If your child takes more MONTEK than he/she should</strong></p><p>Contact your child&rsquo;s doctor immediately for advice. There were no side effects reported in the majority of overdose reports.</p><p>The most frequently occurring symptoms reported with overdose in adults and children included abdominal pain, sleepiness, thirst, headache, vomiting, and hyperactivity.</p><p><strong>If your child forget to give MONTEK to your child</strong></p><p>Try to take this medicine as prescribed. However, if your child misses a dose, just resume the usual schedule of one tablet once daily. Do not give a double dose to make up for a forgotten dose.</p><p><strong>If your child stops taking MONTEK</strong></p><p>This medicine can treat your child&rsquo;s asthma only if your child continues taking it. It is important for your child to continue taking MONTEK for as long as your doctor prescribes. It will help control your child&rsquo;s asthma.</p><p>If you have any further questions on the use of this product, ask your child&rsquo;s doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>In clinical studies with montelukast 4 mg chewable tablets, the most reported side effects (occurring in up to 1 in 10 children) thought to be related to montelukast chewable tablets were:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thirst</p><p>Additionally, the following side effect was reported in clinical studies with montelukast 10 mg film-coated tablets and montelukast 5 mg chewable tablets:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>These were usually mild and occurred at a greater frequency in patients treated with montelukast tablets than placebo (a pill containing no medication).</p><p><strong>Serious side effects</strong></p><p><strong>Talk with your doctor immediately</strong><strong>&nbsp;</strong>if you notice any of the following side effects, which may be serious, and for which you may need urgent medical treatment.</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions including swelling of the face, lips, tongue, and/or throat which may cause difficulty in breathing or swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Behavior and mood related changes: agitation including aggressive behavior or hostility, depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizure</p><p><strong>Rare </strong>(may affect up to 1 in 1,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased bleeding tendency</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tremor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fast or irregular heartbeats (Palpitations)</p><p><strong>Very rare </strong>(may affect up to 1 in 10,000 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Combination of symptoms such as flu-like illness, pins and needles or numbness of arms and legs, worsening of pulmonary symptoms and/or rash (Churg-Strauss syndrome).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood platelet count.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Behavior and mood related changes: hallucinations, disorientation, suicidal thoughts and actions.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling (inflammation) of the lungs.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe skin reactions (erythema multiforme) that may occur without warning.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the liver (hepatitis).</p><p><strong>Other side effects while montelukast has been in the market</strong></p><p><strong>Very common</strong>: (may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Upper respiratory infection</p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhea, nausea, vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated liver enzymes</p><p><strong>Uncommon</strong> (may affect up to 1 in 100 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Behavior and mood related changes: dream abnormalities, including nightmares, trouble sleeping, sleepwalking, irritability, feeling anxious, restlessness.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness, drowsiness, pins and needles/numbness.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nosebleed.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry mouth, indigestion.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bruising, itching, hives.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint or muscle pain, muscle cramps.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bedwetting in children.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weakness/tiredness, feeling unwell, swelling.</p><p><strong>Rare</strong> (the following may affect up to 1 in 1,000 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Behavior and mood related changes: disturbance in attention, memory impairment, uncontrolled muscle movements.</p><p><strong>Very rare</strong> (the following may affect up to 1 in 10,000 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tender red lumps under the skin, most commonly on your shins (erythema nodosum).</p><p>Ask your doctor or pharmacist for more information about side effects. If any of the side effects gets serious, or if you notice any side effects not listed, please tell your doctor or pharmacist.</p><p><strong>To report any side effect(s):</strong></p><p>&bull;&nbsp; <strong><em>Saudi Arabia:</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC)</p><p>o&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp; SFDA Call Center: 19999</p><p>o&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp; Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&bull;&nbsp; <strong><em>Other GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not store above 30&ordm;C</p><p>Do not use <strong>MONTEK</strong><em> </em>after the expiry date which is stated on the carton and on the blister after EXP. The expiry date refers to the last day of that month.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The <strong>active</strong> substance is montelukast. Each tablet contains montelukast sodium which corresponds to 5 mg of montelukast.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The <strong>other</strong> ingredients are mannitol, microcrystalline cellulose, hydroxypropyl cellulose, iron oxide red, croscarmellose sodium, cherry flavor, aspartame (E 951) and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                MONTEK 5 mg chewable tablets are pink, flat, round, with bevel edges, engraved with ‘M5’ on one side and plain on the other.
Available in packages of 30 chewable tablets

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>AJA Pharmaceutical Industries Company, Ltd.</p><p>Hail Industrial City MODON, Street No 32</p><p>PO Box 6979, Hail 55414</p><p>Kingdom of Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>مونتك</strong> هو مضاد لمستقبل ليوكوتراين الذي يعمل على حصر مواد تدعى ليوكوتراينات. تؤدي الليوكوتراينات إلى تضيّق وتورم المجاري الهوائية في الرئة، عن طريق حصر الليوكوتراينات،&nbsp;<strong>يخفف مونتك من أعراض الربو ويساعد في السيطرة عليه</strong><strong>.</strong></p><p dir="RTL">وصف الطبيب <strong>مونتك</strong> لعلاج الربو لدى طفلك ومنع حدوث اعراض هذا المرض خلال النهار والليل.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يستخدم هذا الدواء لعلاج المرضى الذين لم يتم السيطرة على الربو لديهم باستخدام أدويتهم الحالية وبحاجة إلى <strong>علاج</strong> <strong>إضافي</strong>.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يستخدم هذا الدواء أيضا <strong>كعلاج بديل عن الستيرويدات القشرية</strong> المستنشقة للمرضى الذين لم يتناولوا مؤخراً الستيرويدات القشرية عن طريق الفم لعلاج الربو وأظهروا عدم قدرتهم على استخدام الستيرويدات القشرية المستنشقة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يساعد هذا الدواء أيضا <strong>للوقاية من حدوث تضيق المجاري الهوائية</strong> الناتج عن القيام بالتمارين الرياضية.&nbsp;</p><p dir="RTL">سيحدد طبيبك كيفية استخدام هذا الدواء وذلك اعتماداً على الأعراض وشدة حالة الربو الذي تعاني منه أنت وطفلك.&nbsp;</p><p dir="RTL"><strong>ما هو الربو؟&nbsp; </strong></p><p dir="RTL">الربو هو عبارة مرض طويل الأمد.</p><p dir="RTL">يتضمن الربو:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس نتيجة لتضيق المجاري الهوائية. يزداد تضيق المجاري الهوائية سوءاً و يتحسن استجابةً لظروف متعددة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المجاري الهوائية الحساسة التي تتأثر بعوامل عدة، مثل دخان السجائر، غبار الطلع، الهواء البارد، أو التمارين الرياضية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم (التهاب) في بطانة المجاري الهوائية.</p><p dir="RTL">تتضمن أعراض الربو: السعال، أزيز تنفسي، الإحساس بضيق في الصدر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ابلغ طبيبك عن أي مشاكل صحية او حساسيه يعاني منها طفلك حاليا او سبق ان عانى منها.</p><p dir="RTL"><strong>موانع تناول مونتك</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان الطفل يعاني من الحساسية لمونتيلوكاست أو أي من مكونات <strong>مونتك</strong> (المذكورة في الفقرة رقم-6)</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبح مرض الربو أو التنفس اسوأ، يجب عليك ابلاغ الطبيب فوراً.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مونتك</strong> <strong>غير مخصص لعلاج نوبات الربو الحادة</strong>. فإذا حصلت نوبة حادة فعليك اتباع تعليمات الطبيب الذي حددها لطفلك. ويجب عليك الاحتفاظ بالدواء البخاخ للحلق في متناولك من اجل استخدامه عند تعرض الطفل للنوبات الحادة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من المهم أن تعطي لطفلك جميع أدوية الربو التي وصفها له الطبيب. <strong>ويجب عدم تناول مونتك كبديل عن أي أدوية أخرى وصفها الطبيب لطفلك لعلاج الربو. </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي مريض يتناول ادوية لعلاج الربو يجب أن يكون حذراً في حالة الإصابة بمجموعة من الأعراض مثل مرض يشبه الإنفلونزا، الإحساس بوخز خفيف، أو تنمل في الذراعين أو القدمين، زيادة حالة الأعراض التنفسية سوءاً، و/أو طفح، يجب عليك استشارة الطبيب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب ان لا يتناول طفلك حامض الأستيل سالساليك (الأسبرين) او الأدوية المضادة للالتهابات الأخرى (التي تسمى أيضا العقاقير غير السترويدية المضادة للإلتهاب &quot;NSAID&quot;) إذا كانت تجعل مرض الربو أسوأ</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">لا تقم بإعطاء هذا الدواء للأطفال الذين تقل أعمارهم عن سنتين.</p><p dir="RTL"><strong>تناول أدوية أخرى مع مونتك</strong></p><p dir="RTL">&nbsp; الرجاء أن تخبر طبيبك أو الصيدلاني إذا كنت أنت أو طفلك تتناولان حالياً أو تناولتما مؤخراً أو قد تتناولان أدوية أخرى، بما في ذلك الأدوية التي يتم الحصول عليها دون وصفة طبية.</p><p dir="RTL">قد تؤثر بعض الأدوية على آلية عمل هذه الأقراص، أو قد تؤثر الأقراص على آلية عمل الأدوية الأخرى.</p><p dir="RTL">أخبر الطبيب إذا كنت أنت أو طفلك تتناولان حالياً إحدى الأدوية التالية قبل البدء بتناول هذا الدواء:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينوباربيتال (يستخدم لعلاج الصرع).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين (يستخدم لعلاج الصرع).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (يستخدم لعلاج مرض الدرن وبعض انواع العدوى الأخرى).</p><p dir="RTL"><strong>تناول مونتك مع الأطعمة والمشروبات</strong></p><p dir="RTL">يجب عدم تناول <strong>مونتك</strong> مع الطعام مباشرة ويجب ان يؤخذ قبل ساعة واحدة من الطعام او بعده بساعتين.</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL"><u>الاستخدام اثناء الحمل:</u></p><p dir="RTL">النساء الحوامل أو اللاتي يشتبه أنهن حوامل أو يخططن لحدوث الحمل يجب عليهن استشارة الطبيب قبل استخدام <strong>مونتك</strong>. والطبيب هو الذي يقرر ما إذا كانت المرأة يمكن ان تستخدم <strong>مونتك</strong> خلال ذلك.</p><p dir="RTL"><u>الاستخدام اثناء الإرضاع:</u></p><p dir="RTL">لا يعرف ما إذا كان مونتيلوكاست يفرز في حليب الثدي. ويجب استشارة الطبيب قبل تناول هذا الدواء إذا كنت مرضع أو سوف تقومين بذلك.</p><p dir="RTL"><strong>قيادة المركبات واستخدام الآلات</strong></p><p dir="RTL">هذا الجزء لا ينطبق على أقراص <strong>مونتك</strong> 5 ملجم القابلة للمضغ حيث إنها مخصصه لاستخدام من قبل الأطفال من سنتين إلى خمسة سنوات، ولكن تتعلق المعلومات التالية بالمادة الفعالة مونتيلوكاست.</p><p dir="RTL">لا يتوقع أن يؤثر هذا الدواء على قدرتك على قيادة المركبات او استخدام الآلات. ولكن قد تختلف الاستجابة لهذا الدواء من شخص لآخر. وقد ذكرت بعض التقارير حدوث أعراض جانبية معينة (مثل الدوار والنعاس) في حالات نادرة جداً عند تناول هذا الدواء فقد يؤثر في قدرة بعض المرضى على قيادة المركبات استخدام الآلات.</p><p dir="RTL"><strong>معلومات هامة عن بعض مكونات مونتك</strong></p><p dir="RTL">أقراص <strong>مونتك</strong> 5 ملجم القابلة للمضغ تحتوي على اسبارتام وهو مصدر لمادة الفنيل آلانين فإذا كان طفلك يعاني من مشكلة نزول الفنيل كيتون في البول (وهي مشكلة وراثية في الاستقلاب الغذائي أو &quot;الأيض&quot;) فيجب عليك أن تأخذ بعين الاعتبار أن كل قرص 5 ملجم قابل للمضغ يحتوي على الفنيل آلانين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب أن يتناول طفلك هذا الدواء حسب تعليمات الطبيب. لذا فيجب التواصل مع الطبيب أو الصيدلي في حال لم تكن متأكد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب إعطاء قرص واحد للطفل في اليوم حسب تعليمات الطبيب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ويجب ان يعطى طفلك الدواء، حتى لو لم تكن لديه اعراض او نوبة ربو حادة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم تناول هذا الدواء عن طريق الفم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم مضغ الأقراص قبل البلع.</p><p dir="RTL"><strong>للأطفال من عمر 2 إلى </strong><strong>5</strong><strong> سنة</strong></p><p dir="RTL">يعطى قرص واحد <strong>مونتك</strong> 4 ملجم القابل للمضغ للطفل في المساء. يجب عدم تناول <strong>مونتك</strong> مع الطعام مباشرة ويجب ان يؤخذ قبل ساعة واحدة من الطعام او بعده بساعتين.</p><p dir="RTL"><strong>للأطفال من عمر 6 إلى </strong><strong>14</strong><strong> سنة</strong></p><p dir="RTL">قرص واحد <strong>مونتك</strong> 5 ملجم القابلة للمضغ. يجب عدم تناول <strong>مونتك</strong> مع الطعام مباشرة ويجب ان يؤخذ قبل ساعة واحدة من الطعام او بعده بساعتين. وإذا كان طفلك يتناول هذا الدواء فيجب عليك التحقق من أنه لا يستخدم أي ادوية أخرى تحتوي على نفس المادة الفعالة، مونتيلوكاست.</p><p dir="RTL"><strong>إذا تناول طفلك جرعة زائدة من مونتك</strong></p><p dir="RTL">إذا تناول الطفل جرعة زائدة فيجب عليك الاتصال بالطبيب فوراً. لا توجد هناك أعراض جانبية لدى معظم حالات زيادة الجرعة التي وردت في التقارير.</p><p dir="RTL">الأعراض الأكثر شيوعاً المبلغ عنها والناتجة عن الجرعات الزائدة لدى البالغين والأطفال تشمل الألم في البطن، والنعاس، والعطش والصداع، والتقيؤ، وفرط النشاط الحركي.</p><p dir="RTL"><strong>إذا نسيت أن تعطي مونتك لطفلك</strong></p><p dir="RTL">حاول دائما اعطاء هذا الدواء حسب التعليمات تماماً. ولكن إذا نسيت ان تعطي طفلك الجرعة المعتادة في وقتها فيجب عليك استئناف إعطائه الجرعات حسب الجدول المعتاد (مرة واحدة يوميا). ويجب ان لا تعطي الطفل أبداً جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p dir="RTL"><strong>إذا توقف طفلك عن تناول مونتك</strong></p><p dir="RTL">هذا الدواء يقوم بعلاج مرض الربو الذي يعاني منه طفلك إذا استمر على تناوله. فمن المهم ان يستمر الطفل في تناول <strong>مونتك</strong> إذا لم ينصح الطبيب بعكس ذلك، فهذا سيساعد في السيطرة على مرض الربو لدى الطفل.</p><p dir="RTL">وإذا كانت لديك أي اسئلة حول استخدام هذا المنتج عليك الاتصال بالطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كغيره من الأدوية يمكن أن يسبب بعض التأثيرات الجانبية مع انها لا تحدث لدى جميع الأشخاص.</p><p dir="RTL">في دراسات سريرية اجريت على مونتيلوكاست أقراص القابلة للمضغ، كانت الأعراض الجانبية الأكثر شيوعاً التي تم الإبلاغ عنها (حدثت على الأقل لدى 1 من بين كل 10 مريض) والتي يعتقد أنها متعلقة بمونتيلوكاست كانت كما يلي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عطش</p><p dir="RTL">كما وقد تم الإبلاغ عن العرض الجانبي التالي في دراسات سريرية على أقراص مونتيلوكاست 10 ملجم المغلفة وأقراص 5 ملجم القابلة للمضغ:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">وكانت تلك الأعراض غالبا خفيفة وحدثت لدى مرضى الذين تم علاجهم باستخدام مونتيلوكاست بمعدلات أكبر مما كانت لدى مرضى تم علاجهم بلاسيبو (اقراص مشابهة لا تحتوي على أي دواء).</p><p dir="RTL"><strong>أعراض جانبية خطيرة</strong></p><p dir="RTL"><strong>غير شائع </strong>(يؤثر على 1 من 100 أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل حساسية بما فيها ظهور طفح جلدي، تورم بالوجه، الشفتين، اللسان و/أو الحلق مما قد يتسبب في صعوبة التنفس أو البلع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات ذات علاقة بالسلوك والمزاج: التهيج بما في ذلك السلوك العدواني، الارتعاش، الاكتئاب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات (صرع)</p><p dir="RTL"><strong>نادر </strong>(يؤثر على 1 من 1,000 أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة القابلية للنزف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رعشة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفقان بالقلب</p><p dir="RTL"><strong>نادر جدا </strong>(يؤثر على 1 من 10,000 أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مجموعة من الأعراض تشبه مرض الإنفلونزا، الإحساس بوخز خفيف أو تنمل في الذراعين والقدمين، ازدياد حالة الأعراض التنفسية سوءاً و/أو طفح (متلازمة شورج-ستروس).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص في تعداد الصفائح الدموية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات مرتبطة بالسلوك والمزاج: هلوسة، ارتباك، التفكير في الانتحار والإقدام عليه.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم (التهاب) الرئتين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية خطيرة (حمامى متعددة الأشكال) التي قد تحدث دون سابق إنذار.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد.</p><p dir="RTL">تم تسجيل أعراض جانبية أخرى بعد تسويق لمونتيلوكاست</p><p dir="RTL"><strong>شائعة جداً</strong> (قد تؤثر على أكثر من 1 من كل 10 أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجهاز التنفسي العلوي.</p><p dir="RTL"><strong>شائعة</strong> (قد تؤثر على 1 من كل 10 أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال، غثيان، قيء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمّى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى إنزيمات الكبد.</p><p dir="RTL"><strong>غير</strong> <strong>شائعة</strong> (قد تؤثر على 1 من كل 100 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات مرتبطة بالسلوك والمزاج: أحلام غير طبيعية، تشمل كوابيس، مشاكل في النوم، المشي أثناء النوم، هياج، الشعور بالقلق، الشعور بعدم الراحة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار، النعاس، الإحساس بوخز خفيف/تنمل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الأنف.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم، عسر الهضم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كدمات، حكة، شرى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل أو العضلات، معص عضلي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبول الأطفال في الفراش.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بضعف/تعب، الشعور بالمرض، تورم.</p><p dir="RTL"><strong>نادرة</strong> (قد تؤثر على شخص أو أقل من كل 1,000 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات مرتبطة بالسلوك والمزاج: اضطرابات التركيز، قصور الذاكرة، حركات لا إرادية في العضلات.</p><p dir="RTL"><strong>نادرة جداً</strong> (قد تؤثر على شخص أو أقل من كل 10,000 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بروز كتل حمراء تحت الجلد على الساقين (الحمامى العقدة).</p><p dir="RTL">اسأل طبيبك أو الصيدلي لمعلومات إضافية عن الأعراض الجانبية. إذا ازدادت أي من هذه الأعراض سوءًا أو لاحظت أعراض أخرى لم تذكر في هذه النشرة، تواصل مع طبيبك أو الصيدلي.</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية:</strong></p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="height:200px; width:309px"><tbody><tr><td style="width:306px"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ الدوائي</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-11-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهاتف الموحد: 19999</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa &nbsp;</p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">الرجاء الاتصال بالمؤسسات والهيئات الوطنية لكل دولة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدا عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ في درجة حرارة لا تزيد عن 30 درجة مئوية</p><p dir="RTL">لا تتناول <strong>مونتك</strong> بعد تاريخ انتهاء صلاحيته المطبوع على العلبة وهو يشير إلى آخر يوم في ذلك الشهر</p><p dir="RTL">يجب عدم إلقاء أي أدوية في مياه الصرف الصحي او في النفايات المنزلية. وعليك ان تسأل الصيدلي عن كيفية التخلص من الأدوية التي لا تحتاجها. وهذه التدابير تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp; المادة <strong>الفعالة</strong> هي مونتيلوكاست. كل قرص يحتوي على مونتيلوكاست صوديوم ما يعادل 5 ملجم من &quot;مونتيلوكاست&quot;.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات <strong>الأخرى</strong> هي مانيتول، سيليولوز مبلور دقيق، هيدروكسي بروبيل سيليولوز، اكسيد الحديد الأحمر، كروسكارميلوز صوديوم، نكهة الكرز، اسبارتام (E951)، ستيارات المغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص <strong>مونتك</strong> 5 ملجم القابلة للمضغ هي اقراص بلون وردي مستديرة ومسطحة وذات حواف مشطوفه، منقوش على أحد جانبها &rsquo;M5&rsquo; والجانب الآخر سادة.</p><p dir="RTL">تتوفر بعبوة من 30 قرص قابل للمضغ.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة آجا للصناعات الصيدلانية</p><p dir="RTL">المدينة الصناعية مدن بحائل، شارع رقم 32</p><p dir="RTL">حائل 55414، ص.ب. 6979</p><p dir="RTL">المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             04/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MONTEK 5 mg chewable Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each chewable tablet contains montelukast sodium, which is equivalent to 5 mg montelukast. 
Excipients with known effect: This medicine contains aspartame (E 951).
For the full list of excipients, see section 6

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Chewable tablet.
Pink, flat, round, with bevel edges, engraved with ‘M5’ on one side and plain on the other.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>MONTEK </strong>is indicated in the treatment of asthma as add-on therapy in those 2- to 5-year- old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom &ldquo;as-needed&rdquo; short-acting &beta;-agonists provide inadequate clinical control of asthma.</p><p><strong>MONTEK </strong>may also be an alternative treatment option to low-dose inhaled corticosteroids for 2- to 5-year-old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids (see section 4.2).</p><p><strong>MONTEK </strong>is also indicated in the prophylaxis of asthma from 2 years of age and older in which the predominant component is exercise-induced bronchoconstriction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>This medicinal product is to be given to a child under adult supervision. The recommended dose for pediatric patients 6-14 years of age is one 5 mg chewable tablet daily to be taken in the evening. If taken in connection with food, <strong>MONTEK </strong>should be taken 1 hour before or 2 hours after food. No dosage adjustment within this age group is necessary.</p><p><u>General recommendations</u></p><p>The therapeutic effect of <strong>MONTEK </strong>on parameters of asthma control occurs within one day. Patients should be advised to continue taking <strong>MONTEK </strong>even if their asthma is under control, as well as during periods of worsening asthma.</p><p>&nbsp;</p><p>No dosage adjustment is necessary for patients with renal insufficiency, or mild to moderate hepatic impairment. There are no data on patients with severe hepatic impairment. The dosage is the same for both male and female patients.</p><p><strong><u>MONTEK </u></strong><u>as an alternative treatment option to low-dose inhaled corticosteroids for mild,</u> <u>persistent asthma</u></p><p>Montelukast is not recommended as monotherapy in patients with moderate persistent asthma. The use of montelukast as an alternative treatment option to low-dose inhaled corticosteroids for children with mild persistent asthma should only be considered for patients who do not have a recent history of serious asthma attacks that required oral corticosteroid use and who have demonstrated that they are not capable of using inhaled corticosteroids (see section 4.1). Mild persistent asthma is defined as asthma symptoms more than once a week but less than once a day, nocturnal symptoms more than twice a month but less than once a week, normal lung function between episodes. If satisfactory control of asthma is not achieved at follow-up (usually within one month), the need for an additional or different anti-inflammatory therapy based on the step system for asthma therapy should be evaluated. Patients should be periodically evaluated for their asthma control.</p><p><u>Therapy with MONTEK in relation to other treatments for asthma</u></p><p>When treatment with MONTEK is used as add-on therapy to inhaled corticosteroids, MONTEK should not be abruptly substituted for inhaled corticosteroids (see section 4.4). 10 mg film-coated tablets are available for adults and adolescents 15 years of age and older.</p><p><em>Pediatric population</em></p><p>Do not give <strong>MONTEK </strong>5 mg chewable tablets to children less than 6 years of age. The safety and efficacy of <strong>MONTEK </strong>5 mg chewable tablets in children less than 6 years of age has not been established.</p><p><strong>MONTEK </strong>4 mg chewable tablets are available for pediatric patients 2 to 5 years of age. <u>Method of administration</u></p><p>Oral use.</p><p>The tablets are to be chewed before swallowing.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be advised never to use oral montelukast to treat acute asthma attacks and to keep their usual appropriate rescue medication for this purpose readily available. If an acute attack occurs, a short-acting inhaled &beta;-agonist should be used. Patients should seek their doctors&#39; advice as soon as possible if they need more inhalations of short-acting &beta;- agonists than usual.</p><p>Montelukast should not be abruptly substituted for inhaled or oral corticosteroids.</p><p>&nbsp;</p><p>There are no data demonstrating that oral corticosteroids can be reduced when montelukast is given concomitantly.</p><p>In rare cases, patients on therapy with anti-asthma agents including montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These cases have been sometimes associated with the reduction or withdrawal of oral corticosteroid therapy. Although a causal relationship with leukotriene receptor antagonism has not been established, physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. Patients who develop these symptoms should be reassessed and their treatment regimens evaluated.</p><p>Treatment with montelukast does not alter the need for patients with aspirin-sensitive asthma to avoid taking aspirin and other non-steroidal anti-inflammatory drugs.</p><p><strong>MONTEK </strong>contains aspartame, a source of phenylalanine. Patients with phenylketonuria should take into account that each 4 mg chewable tablet contains phenylalanine in an amount equivalent to 0.674 mg phenylalanine per dose.</p><p>Neuropsychiatric Events</p><p>Serious neuropsychiatric (NP) events have been reported with use of montelukast. These post-marketing reports have been highly variable and included, but were not limited to, agitation, aggressive behavior or hostility, anxiousness, depression, disorientation, disturbance in attention, dream abnormalities, dysphemia (stuttering), hallucinations, insomnia, irritability, memory impairment, obsessive-compulsive symptoms, restlessness, somnambulism, suicidal thoughts and behavior (including suicide), tic, and tremor. NP events have been reported in adult, adolescent, and pediatric patients with and without a previous history of psychiatric disorder. NP events have been reported mostly during montelukast treatment, but some were reported after montelukast discontinuation. Animal studies showed that montelukast distributes into the brain in rats [see Clinical Pharmacology (12.3)]; however, the mechanisms underlying montelukast -associated NP events are currently not well understood. Based upon the available data, it is difficult to identify risk factors for or quantify the risk of NP events with montelukast use.</p><p>Because of the risk of NP events, the benefits of montelukast may not outweigh the risks in some patients, particularly when the symptoms of disease may be mild and adequately treated with alternative therapies. Reserve use of montelukast for patients with allergic rhinitis who have an inadequate response or intolerance to alternative therapies [see Indications and Usage (1.3)]. In patients with asthma or exercise-induced bronchoconstriction, consider the benefits and risks before prescribing montelukast.</p><p>Discuss the benefits and risks of montelukast use with patients and caregivers when prescribing montelukast. Advise patients and/or caregivers to be alert for changes in behavior or for new NP symptoms when taking montelukast. If changes in behavior are observed, or if new NP symptoms or suicidal thoughts and/or behavior occur, advise patients to discontinue montelukast and contact a healthcare provider immediately. In</p><p>&nbsp;</p><p>many cases, symptoms resolved after stopping montelukast therapy; however, in some cases symptoms persisted after discontinuation of montelukast. Therefore, continue to monitor and provide supportive care until symptoms resolve. Re-evaluate the benefits and risks of restarting treatment with montelukast if such events occur.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interactions studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following medicinal products: theophylline, prednisone, prednisolone, oral contraceptives (ethinyl estradiol/norethindrone 35/1), terfenadine, digoxin and warfarin.</p><p>The area under the plasma concentration curve (AUC) for montelukast was decreased approximately 40% in subjects with co-administration of phenobarbital. Since montelukast is metabolized by CYP 3A4, 2C8, and 2C9, caution should be exercised, particularly in children, when montelukast is co-administered with inducers of CYP 3A4, 2C8, and 2C9, such as phenytoin, phenobarbital and rifampicin.</p><p><em>In vitro </em>studies have shown that montelukast is a potent inhibitor of CYP 2C8. However, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of medicinal products primarily metabolized by CYP 2C8) demonstrated that montelukast does not inhibit CYP 2C8 <em>in vivo. </em>Therefore, montelukast is not anticipated to markedly alter the metabolism of medicinal products metabolized by this enzyme (e.g., paclitaxel, rosiglitazone, and repaglinide).</p><p><em>In vitro </em>studies have shown that montelukast is a substrate of CYP 2C8, and to a less significant extent, of 2C9, and 3A4. In a clinical drug-drug interaction study involving montelukast and gemfibrozil (an inhibitor of both CYP 2C8 and 2C9) gemfibrozil increased the systemic exposure of montelukast by 4.4-fold. No routine dosage adjustment of montelukast is required upon co-administration with gemfibrozil or other potent inhibitors of CYP 2C8, but the physician should be aware of the potential for an increase in adverse reactions.</p><p>Based on <em>in vitro </em>data, clinically important drug interactions with less potent inhibitors of CYP 2C8 (e.g., trimethoprim) are not anticipated. Co-administration of montelukast with itraconazole, a strong inhibitor of CYP 3A4, resulted in no significant increase in the systemic exposure of montelukast.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Animal studies do not indicate harmful effects with respect to effects on pregnancy or embryonal/fetal development.</p><p>Limited data from available pregnancy databases do not suggest a causal relationship between Montelukast and malformations (i.e. limb defects) that have been rarely reported in worldwide post-marketing experience.</p><p>&nbsp;</p><p><strong>MONTEK </strong>may be used during pregnancy only if it is considered to be clearly essential.</p><p><u>Breast-feeding</u></p><p>Studies in rats have shown that montelukast is excreted in milk (see section 5.3). It is unknown whether montelukast/metabolites are excreted in human milk.</p><p><strong>MONTEK </strong>may be used in breast-feeding mothers only if it is considered to be clearly essential.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>MONTEK </strong>has no or negligible influence on the ability to drive and use machines.</p><p>However, individuals have reported drowsiness or dizziness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast has been evaluated in clinical studies in patients with persistent asthma as follows:</p><p>&bull;&nbsp;&nbsp; 10 mg film-coated tablets in approximately 4,000 adult and adolescent patients 15 years of age and older</p><p>&bull;&nbsp; 5 mg chewable tablets in approximately 1,750 pediatric patients 6 to 14 years of age, and</p><p>&bull;&nbsp; 4 mg chewable tablets in 851 pediatric patients 2 to 5 years of age.</p><p>The following drug-related adverse reactions in clinical studies were reported commonly (&ge;1/100 to &lt;1/10) in patients treated with montelukast and at a greater incidence than in patients treated with placebo:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Body System Class</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Adult and Adolescent Patients 15 years and older (two 12-week studies; n=795)</strong></p></td><td style="vertical-align:top"><p><strong>Pediatric Patients 6 to 14 years old</strong></p><p><strong>(one 8-week study; n=201)</strong></p><p><strong>(two 56-week studies; n=615)</strong></p></td><td style="vertical-align:top"><p><strong>Pediatric Patients 2 to 5 years old</strong></p><p><strong>(one 12-week study; n=461)</strong></p><p><strong>(one 48-week study; n=278)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastro-intestinal disorders</strong></p></td><td style="vertical-align:top"><p>abdominal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>thirst</p></td></tr></tbody></table><p>With prolonged treatment in clinical trials with a limited number of patients for up to 2 years for adults, and up to 12 months for pediatric patients 6 to 14 years of age, the safety profile did not change.</p><p>&nbsp;</p><p>Cumulatively, 502 pediatric patients 2 to 5 years of age were treated with montelukast for at least 3 months, 338 for 6 months or longer, and 534 patients for 12 months or longer. With prolonged treatment, the safety profile did not change in these patients either.</p><p><u>Tabulated list of Adverse Reactions</u></p><p>Adverse reactions reported in post-marketing use are listed, by System Organ Class and specific Adverse Reactions, in the table below. Frequency Categories were estimated based on relevant clinical trials.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Adverse Reactions</strong></p></td><td style="vertical-align:top"><p><strong>Frequency Category*</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Infections and infestations</p></td><td colspan="3" style="vertical-align:top"><p>upper respiratory infection&dagger;</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood disorders</p></td><td style="vertical-align:top"><p>and</p></td><td style="vertical-align:top"><p>lymphatic</p></td><td style="vertical-align:top"><p>system</p></td><td colspan="3" style="vertical-align:top"><p>increased bleeding tendency</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>thrombocytopenia</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td colspan="4" rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>Immune system disorders</p></td><td colspan="3" style="vertical-align:top"><p>hypersensitivity reactions including anaphylaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>hepatic eosinophilic infiltration</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td colspan="4" rowspan="3" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Psychiatric disorders</p></td><td colspan="3" style="vertical-align:top"><p>dream abnormalities including nightmares,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; insomnia, somnambulism, anxiety, agitation including aggressive behavior or hostility, depression, psychomotor hyperactivity (including irritability, restlessness, tremor&sect;)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>disturbance&nbsp;&nbsp; in impairment, tic</p></td><td style="vertical-align:top"><p>attention,</p></td><td style="vertical-align:top"><p>memory</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>hallucinations,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disorientation, suicidal thinking and behavior (suicidality), obsessive-compulsive symptoms, dysphemia</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Very Rare</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Nervous system disorders</p></td><td colspan="3" style="vertical-align:top"><p>dizziness,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drowsiness, paraesthesia/hypoesthesia, seizure</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Cardiac disorders</p></td><td colspan="3" style="vertical-align:top"><p>palpitations</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="4" rowspan="3" style="vertical-align:top"><p>&nbsp;</p><p>Respiratory, thoracic and mediastinal disorders</p></td><td colspan="3" style="vertical-align:top"><p>epistaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Churg-Strauss Syndrome (CSS) (see section 4.4)</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>pulmonary eosinophilia</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Gastro-intestinal disorders</p></td><td colspan="3" style="vertical-align:top"><p>diarrhea&Dagger;, nausea&Dagger;, vomiting&Dagger;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>dry mouth, dyspepsia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>elevated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; levels&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serum transaminases (ALT, AST)</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>hepatitis (including cholestatic, hepatocellular, and mixed-pattern liver injury).</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Very Rare</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Skin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp; subcutaneous&nbsp;&nbsp;&nbsp;&nbsp; tissue disorders</p></td><td style="vertical-align:top"><p>rash&Dagger;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>bruising, urticaria, pruritus</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>angioedema</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>erythema&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nodosum,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; erythema multiforme</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp; connective tissue disorders</p></td><td style="vertical-align:top"><p>arthralgia, myalgia including muscle cramps</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>enuresis in children</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>pyrexia&Dagger;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>asthenia/fatigue, malaise, edema</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*Frequency Category: Defined for each Adverse Reaction by the incidence reported in the clinical trials data base: Very Common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1,000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1,000), Very Rare (&lt;1/10,000).</p><p>&dagger;This adverse experience, reported as Very Common in the patients who received</p><p>montelukast, was also reported as Very Common in the patients who received placebo in clinical trials.</p><p>&Dagger;This adverse experience, reported as Common in the patients who received montelukast,</p><p>was also reported as Common in the patients who received placebo in clinical trials.</p><p>&sect; Frequency Category: Rare</p></td></tr></tbody></table><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p>To report any side effect(s):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="height:150px; width:377px"><tbody><tr><td style="width:373px"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o&nbsp; SFDA Call Center: 19999</p><p>o&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp; Website: <u>https://ade.sfda.gov.sa</u></p></td></tr></tbody></table><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:111.1pt;margin-top:7.5pt;width:251.55pt;height:68.2pt;z-index:-251658752;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".96pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-left:.25in;text-indent:-14.45pt;
     line-height:13.2pt;mso-line-height-rule:exactly;mso-list:l1 level1 lfo1;
     tab-stops:.25in'><![if !supportLists]><span style='font-family:Symbol;
     mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span>The National
     Pharmacovigilance Centre<span style='letter-spacing:-.8pt'> </span>(NPC)<o:p></o:p></p>
     <p class=MsoNormal style='margin-left:35.95pt;line-height:13.15pt;
     mso-line-height-rule:exactly'><span style='font-family:"Courier New";
     mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman"'>o
     </span>Fax: +966-11-205-7662<o:p></o:p></p>
     <p class=MsoNormal style='margin-left:.7in;text-indent:-14.5pt;line-height:
     12.6pt;mso-line-height-rule:exactly;mso-list:l1 level2 lfo1;tab-stops:
     50.45pt'><![if !supportLists]><span style='font-family:"Courier New";
     mso-fareast-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>SFDA Call Center:<span style='letter-spacing:-.45pt'> </span>19999<o:p></o:p></p>
     <p class=MsoNormal style='margin-left:.7in;text-indent:-14.45pt;
     line-height:12.6pt;mso-line-height-rule:exactly;mso-list:l1 level2 lfo1;
     tab-stops:50.45pt'><![if !supportLists]><span style='font-family:"Courier New";
     mso-fareast-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>E-mail:<span style='color:blue;letter-spacing:.1pt'> </span><a
     href="mailto:npc.drug@sfda.gov.sa"><span style='color:blue'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoNormal style='margin-left:.7in;text-indent:-14.5pt;line-height:
     13.15pt;mso-line-height-rule:exactly;mso-list:l1 level2 lfo1;tab-stops:
     50.45pt'><![if !supportLists]><span style='font-family:"Courier New";
     mso-fareast-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>Website:<span style='color:blue;letter-spacing:-.15pt'> </span><u
     style='text-underline:blue'><span style='color:blue'>https://ade.sfda.gov.sa</span></u><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC states:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In chronic asthma studies, montelukast has been administered at doses up to 200 mg/day to adult patients for 22 weeks and in short-term studies, up to 900 mg/day to patients for approximately one week without clinically important adverse experiences.</p><p>There have been reports of acute overdose in post-marketing experience and clinical studies with montelukast. These include reports in adults and children with a dose as high as 1,000 mg (approximately 61 mg/kg in 42 months old child). The clinical and laboratory findings observed were consistent with the safety profile in adults and pediatric patients. There were no adverse experiences in the majority of overdose reports.</p><p><u>Symptoms of overdose</u></p><p>The most frequently occurring adverse experiences were consistent with the safety profile of montelukast and included abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity.</p><p><u>Management of overdose</u></p><p>No specific information is available on the treatment of overdose with montelukast. It is not known whether montelukast is dialysable by peritoneal- or haemo-dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Leukotriene receptor antagonist ATC-Code: R03D C03</p><p><u>Mechanism of action</u></p><p>The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are potent inflammatory eicosanoids released from various cells including mast cells and eosinophils. These important pro- asthmatic mediators bind to cysteinyl leukotriene receptors (CysLT) found in the human airway and cause airway actions, including bronchoconstriction, mucous secretion, vascular permeability, and eosinophil recruitment.</p><p><u>Pharmacodynamic effects</u></p><p>Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. In clinical studies, montelukast inhibits bronchoconstriction due to inhaled LTD4 at doses as low as 5 mg. Bronchodilation was observed within 2 hours of oral administration. The bronchodilation effect caused by a &beta;-agonist was additive to that caused by montelukast. Treatment with montelukast inhibited both early- and late-phase bronchoconstriction due to antigen challenge. Montelukast, compared with placebo, decreased peripheral blood eosinophils in adult and pediatric patients. In a separate study, treatment with montelukast significantly decreased eosinophils in the airways (as measured in sputum). In adult and pediatric patients 2 to 14 years of age, montelukast, compared with placebo, decreased peripheral blood eosinophils while improving clinical asthma control.</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>In studies in adults, montelukast, 10 mg once daily, compared with placebo, demonstrated significant improvements in morning FEV1 (10.4% vs 2.7% change from baseline), AM peak expiratory flow rate (PEFR) (24.5 L/min vs 3.3 L/min change from baseline), and significant decrease in total &beta;-agonist use (-26.1% vs -4.6% change from baseline). Improvement in patient-reported daytime and nighttime asthma symptoms scores was significantly better than placebo.</p><p>Studies in adults demonstrated the ability of montelukast to add to the clinical effect of inhaled corticosteroid (% change from baseline for inhaled beclomethasone plus montelukast vs beclomethasone, respectively for FEV1: 5.43% vs 1.04%; &beta;-agonist use: - 8.70% vs 2.64%). Compared with inhaled beclomethasone (200 &mu;g twice daily with a spacer device), montelukast demonstrated a more rapid initial response, although over the 12-week study, beclomethasone provided a greater average treatment effect (% change from baseline for montelukast vs beclomethasone, respectively for FEV1: 7.49% vs 13.3%; &beta;-agonist use: -28.28% vs -43.89%). However, compared with beclomethasone, a high percentage of patients treated with montelukast achieved similar clinical responses (e.g., 50% of patients treated with beclomethasone achieved an improvement in FEV1 of approximately 11% or more over baseline while approximately 42% of patients treated with montelukast achieved the same response).</p><p>In a 12-week, placebo-controlled study in pediatric patients 2 to 5 years of age, montelukast</p><p>4 mg once daily improved parameters of asthma control compared with placebo irrespective of concomitant controller therapy (inhaled/nebulized corticosteroids or inhaled/nebulized sodium cromoglycate). Sixty percent of patients were not on any other controller therapy. Montelukast improved daytime symptoms (including coughing, wheezing, trouble breathing and activity limitation) and nighttime symptoms compared with placebo. Montelukast also decreased &ldquo;as needed&rdquo; &beta;-agonist use and corticosteroid rescue for worsening asthma compared with placebo. Patients receiving montelukast had more days without asthma than those receiving placebo. A treatment effect was achieved after the first dose.</p><p>In a 12-month, placebo-controlled study in pediatric patients 2 to 5 years of age with mild asthma and episodic exacerbations, montelukast 4 mg once daily significantly (p&le;0.001) reduced the yearly rate of asthma exacerbation episodes (EE) compared with placebo (1.60 EE vs. 2.34 EE, respectively), [EE defined as &ge;3 consecutive days with daytime symptoms requiring &beta;-agonist use, or corticosteroids (oral or inhaled), or hospitalization for asthma]. The percentage reduction in yearly EE rate was 31.9%, with a 95% CI of 16.9, 44.1.</p><p>In a placebo-controlled study in pediatric patients 6 months to 5 years of age who had intermittent asthma but did not have persistent asthma, treatment with montelukast was administered over a 12-month period, either as a once-daily 4 mg regimen or as a series of 12-day courses that each were started when an episode of intermittent symptoms began. No significant difference was observed between patients treated with montelukast 4 mg or placebo in the number of asthma episodes culminating in an asthma attack, defined as an asthma episode requiring utilization of health-care resources such as an unscheduled visit</p><p>&nbsp;</p><p>to a doctor&#39;s office, emergency room, or hospital; or treatment with oral, intravenous, or intramuscular corticosteroid.</p><p>In an 8-week study in pediatric patients 6 to 14 years of age, montelukast 5 mg once daily, compared with placebo, significantly improved respiratory function (FEV1 8.71% vs 4.16% change from baseline; AM PEFR 27.9 L/min vs 17.8 L/min change from baseline) and decreased &ldquo;as-needed&rdquo; &beta;-agonist use (-11.7% vs +8.2% change from baseline).</p><p>In a 12-month study comparing the efficacy of montelukast to inhaled fluticasone on asthma control in pediatric patients 6 to 14 years of age with mild persistent asthma, montelukast was non-inferior to fluticasone in increasing the percentage of asthma rescue- free days (RFDs), the primary endpoint. Averaged over the 12-month treatment period, the percentage of asthma RFDs increased from 61.6 to 84.0 in the montelukast group and from</p><p>60.9 to 86.7 in the fluticasone group. The between group difference in LS mean increase in the percentage of asthma RFDs was statistically significant (-2.8 with a 95% CI of -4.7,</p><p>-0.9), but within the limit pre-defined to be clinically not inferior. Both montelukast and fluticasone also improved asthma control on secondary variables assessed over the 12 months treatment period:</p><p>FEV1 increased from 1.83 L to 2.09 L in the montelukast group and from 1.85 L to 2.14 L in the fluticasone group. The between-group difference in LS mean increase in FEV1 was</p><p>-0.02 L with a 95% CI of -0.06, 0.02. The mean increase from baseline in % predicted FEV1 was 0.6% in the montelukast treatment group, and 2.7% in the fluticasone treatment group. The difference in LS means for the change from baseline in the %&nbsp; predicted&nbsp; FEV1 was significant: -2.2% with a 95% CI of -3.6, -0.7.</p><p>The percentage of days with &beta;-agonist use decreased from 38.0 to 15.4 in the montelukast group, and from 38.5 to 12.8 in the fluticasone group. The between group difference in LS means for the percentage of days with &beta;-agonist use was significant: 2.7 with a 95% CI of 0.9, 4.5.</p><p>The percentage of patients with an asthma attack (an asthma attack being defined as a period of worsening asthma that required treatment with oral steroids, an unscheduled visit to the doctor&#39;s office, an emergency room visit, or hospitalization) was 32.2 in the montelukast group and 25.6 in the fluticasone group; the odds ratio (95% CI) being significant: equal to 1.38 (1.04, 1.84).</p><p>The percentage of patients with systemic (mainly oral) corticosteroid use during the study period was 17.8% in the montelukast group and 10.5% in the fluticasone group. The between group difference in LS means was significant: 7.3% with a 95% CI of 2.9; 11.7.</p><p>Significant reduction of exercise-induced bronchoconstriction (EIB) was demonstrated in a 12-week study in adults (maximal fall in FEV1 22.33% for montelukast vs 32.40% for placebo; time to recovery to within 5% of baseline FEV1 44.22 min vs 60.64 min). This effect was consistent throughout the 12-week study period. Reduction in EIB was also demonstrated in a short-term study in pediatric patients 6 to 14 years of age (maximal fall in FEV1 18.27% vs 26.11%; time to recovery to within 5% of baseline FEV1 17.76 min vs</p><p>&nbsp;</p><p>27.98 min). The effect in both studies was demonstrated at the end of the once-daily dosing interval.</p><p>In aspirin-sensitive asthmatic patients receiving concomitant inhaled and/or oral corticosteroids, treatment with montelukast, compared with placebo, resulted in significant improvement in asthma control (FEV1 8.55% vs -1.74% change from baseline and decrease in total &beta;-agonist use -27.78% vs 2.09% change from baseline).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Montelukast is rapidly absorbed following oral administration. For the 10 mg film-coated tablet, the mean peak plasma concentration (Cmax) is achieved 3 hours (Tmax) after administration in adults in the fasted state. The mean oral bioavailability is 64%. The oral bioavailability and Cmax are not influenced by a standard meal. Safety and efficacy were demonstrated in clinical trials where the 10 mg film-coated tablet was administered without regard to the timing of food ingestion.</p><p>For the 5 mg chewable tablet, the Cmax is achieved in 2 hours after administration in adults in the fasted state. The mean oral bioavailability is 73% and is decreased to 63% by a standard meal.</p><p>After administration of the 4 mg chewable tablet to pediatric patients 2 to 5 years of age in the fasted state, Cmax is&nbsp;achieved 2 hours after administration. The mean Cmax is&nbsp;66% higher while mean Cmin is lower than in adults receiving a 10 mg tablet.</p><p><u>Distribution</u></p><p>Montelukast is more than 99% bound to plasma proteins. The steady-state volume of distribution of montelukast averages 8-11 liters. Studies in rats with radiolabelled montelukast indicate minimal distribution across the blood-brain barrier. In addition, concentrations of radiolabelled material at 24 hours post-dose were minimal in all other tissues.</p><p><u>Biotransformation</u></p><p>Montelukast is extensively metabolized. In studies with therapeutic doses, plasma concentrations of metabolites of montelukast are undetectable at steady state in adults and children.</p><p>Cytochrome P450 2C8 is the major enzyme in the metabolism of montelukast. Additionally, CYP 3A4 and 2C9 may have a minor contribution, although itraconazole, an inhibitor of CYP 3A4, was shown not to change pharmacokinetic variables of montelukast in healthy subjects that received 10 mg montelukast daily. Based on <em>in vitro </em>results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6. The contribution of metabolites to the therapeutic effect of montelukast is minimal.</p><p><u>Elimination</u></p><p>The plasma clearance of montelukast averages 45 ml/min in healthy adults. Following an oral dose of radiolabelled montelukast, 86% of the radioactivity was recovered in 5-day faecal collections and &lt;0.2% was recovered in urine. Coupled with estimates of</p><p>&nbsp;</p><p>montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively via the bile.</p><p><u>Characteristics in Patients</u></p><p>No dosage adjustment is necessary for the elderly or mild to moderate hepatic insufficiency. Studies in patients with renal impairment have not been undertaken. Because montelukast and its metabolites are eliminated by the biliary route, no dose adjustment is anticipated to be necessary in patients with renal impairment. There are no data on the pharmacokinetics of montelukast in patients with severe hepatic insufficiency (Child-Pugh score &gt;9).</p><p>With high doses of montelukast (20- and 60-fold the recommended adult dose), a decrease in plasma theophylline concentration was observed. This effect was not seen at the recommended dose of 10 mg once daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In animal toxicity studies, minor serum biochemical alterations in ALT, glucose, phosphorus and triglycerides were observed which were transient in nature. The signs of toxicity in animals were increased excretion of saliva, gastro-intestinal symptoms, loose stools and ion imbalance. These occurred at dosages which provided &gt;17-fold the systemic exposure seen at the clinical dosage. In monkeys, the adverse effects appeared at doses from 150 mg/kg/day (&gt;232-fold the systemic exposure seen at the clinical dose). In animal studies, montelukast did not affect fertility or reproductive performance at systemic exposure exceeding the clinical systemic exposure by greater than 24-fold. A slight decrease in pup body weight was noted in the female fertility study in rats at 200 mg/kg/day (&gt;69-fold the clinical systemic exposure). In studies in rabbits, a higher incidence of incomplete ossification, compared with concurrent control animals, was seen at systemic exposure &gt;24-fold the clinical systemic exposure seen at the clinical dose. No abnormalities were seen in rats. Montelukast has been shown to cross the placental barrier and is excreted in breast milk of animals.</p><p>No deaths occurred following a single oral administration of montelukast sodium at doses up to 5,000 mg/kg in mice and rats (15,000 mg/m2 and 30,000 mg/m2 in mice and rats, respectively), the maximum dose tested. This dose is equivalent to 25,000 times the recommended daily adult human dose (based on an adult patient weight of 50 kg).</p><p>Montelukast was determined not to be phototoxic in mice for UVA, UVB or visible light spectra at doses up to 500 mg/kg/day (approximately &gt;200-fold based on systemic exposure).</p><p>Montelukast was neither mutagenic in <em>in vitro </em>and <em>in vivo </em>tests nor tumorigenic in rodent species.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol</p><p>Microcrystalline cellulose</p><p>Hydroxypropyl cellulose</p><p>Iron oxide red</p><p>Croscarmellose sodium</p><p>Cherry flavor</p><p>Aspartame (E 951)</p><p>Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alu/Alu blister packs, each containing 30 chewable tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AJA Pharmaceutical Industries Company, Ltd.
 Hail Industrial City MODON, Street No 32 
PO Box 6979, Hail 55414
Kingdom of Saudi Arabia Tel: +966 11 268 7900

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04 April 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>